Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven join forces to combat neurological diseases

May 29, 2013

Stellar, the collaboration between Janssen, J&J Innovation, VIB, KU Leuven and UZ Leuven, is launched to overcome the inefficiencies in translating basic molecular insights to diagnostics and therapeutics for neurodegenerative diseases. Janssen and Johnson & Johnson Innovation are committing up to 5 million Euros for this project over a five-year period. They will sponsor academic research projects from VIB, KU Leuven and UZ Leuven.

"Developing a new drug takes lots of time, especially for complex diseases such as Alzheimer's. We are convinced that we can increase the chance of success if we, as a research institute, join forces with a pharmaceutical company like Janssen," Johan Cardoen (Managing Director VIB).

"At Janssen Research & Development, we are deeply committed to patients with neurodegenerative diseases and to the health care professionals who care for them," said Husseini Manji, MD, Global Head, Neuroscience. "We believe that collaboration with external innovators is essential to drive the types of discoveries that will bring forth the treatments of tomorrow for neurodegenerative diseases."

"At Johnson & Johnson Innovation, accelerating the most promising early-stage science in collaboration with leading academic centres around the world is how we will continue to make improvements in the health and happiness of people worldwide," commented Patrick Verheyen, head of the Johnson & Johnson Innovation centre in London.

Stellar: joining forces to combat neurological diseases

This innovative collaboration will address the funding gap in Flanders for translational projects and will result in relevant neuroprotective therapeutic strategies by enabling multidisciplinary research projects between basic molecular neuroscientists, experts in cognitive animal model testing, clinical neurologists, human imaging specialists and Janssen R&D scientists.

Stellar seeks to attract top researchers in the BeNeLux scientific community to submit proposals for cutting-edge research in neurodegenerative disorders. The Johnson & Johnson companies will collaborate initially with VIB, KU Leuven and The University Hospital Leuven to create opportunities for collaborative research. Other academic institutions are encouraged to join the project as its next phase begins later this year.

For more information about the initiative and the submission process, please visit http://www.stellar-project.be (available on June 17, 2013).
-end-


VIB (the Flanders Institute for Biotechnology)

Related Neurodegenerative Diseases Articles from Brightsurf:

Bringing drugs to the brain with nanoparticles to treat neurodegenerative diseases
Researchers from the Institut national de la recherche scientifique (INRS) have shown that nanoparticles could be used to deliver drugs to the brain to treat neurodegenerative diseases.

First 'pathoconnectome' could point toward new treatments for neurodegenerative diseases
Scientists from the John A. Moran Eye Center at the University of Utah have achieved another first in the field of connectomics, which studies the synaptic connections between neurons.

Unlocking the mystery of tau for treatment of neurodegenerative diseases
A team of researchers from various collaborating universities and hospitals in Japan has uncovered crucial molecular details regarding the activity of the ''tau'' protein, promising to revolutionize the therapy of tau-induced neurodegenerative diseases.

Investigational drug stops toxic proteins tied to neurodegenerative diseases
An investigational drug that targets an instigator of the TDP-43 protein, a well-known hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), may reduce the protein's buildup and neurological decline associated with these disorders, suggests a pre-clinical study from researchers at Penn Medicine and Mayo Clinic.

Inhibition of sphingolipid metabolism and neurodegenerative diseases
Disrupting the production of a class of lipids known as sphingolipids in neurons improved symptoms of neurodegeneration and increased survival in a mouse model.

How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases
How understanding the dynamics of yeast prions can shed light on neurodegenerative diseases

New family of molecules to join altered receptors in neurodegenerative diseases
An article published in the Journal of Medicinal Chemistry shows a new family of molecules with high affinity to join imidazoline receptors, which are altered in the brain of those patients with neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's.

Examining diagnoses of stress-related disorders, risk of neurodegenerative diseases
Researchers investigated how stress-related disorders (such as posttraumatic stress disorder, adjustment disorder and stress reactions) were associated with risk for neurodegenerative diseases, including Alzheimer and Parkinson disease and amyotrophic lateral sclerosis (ALS), using data from national health registers in Sweden.

Toxic protein, linked to Alzheimer's and neurodegenerative diseases, exposed in new detail
The protein tau has long been implicated in Alzheimer's and a host of other debilitating brain diseases.

Study uncovers unexpected connection between gliomas, neurodegenerative diseases
New basic science and clinical research identifies TAU, the same protein studied in the development of Alzheimer's, as a biomarker for glioma development.

Read More: Neurodegenerative Diseases News and Neurodegenerative Diseases Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.